Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
6Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
Instil Bio, Inc. (TIL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
1Distinct source URLs
4High confidence
0.734Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Instil Bio, Inc. Suppliers
Ticker
Name
Confidence
Evidence
IMMUNEONCO-BIOPHARMACEUTICALS-SHANGHAI-INC
IMMUNEONCO-BIOPHARMACEUTICALS-SHANGHAI-INC
92%
As part of the IO Collaboration Agreement, Axion Bio made a $ 10.0 million upfront payment to ImmuneOnco during the year ended December 31, 2024.
Instil Bio, Inc. Customers
Ticker
Name
Confidence
Evidence
CLOSING-DATE-COMPLEX-THERAPEUTICS-LLC
CLOSING-DATE-COMPLEX-THERAPEUTICS-LLC
62%
settlement gain on terminated contracts in 2025. Interest Income, Interest Expense, Other Rental Income, Gain on Contract Termination, and Other (Expense) Income, Net Interest income, interest expens…
COMPLEX-THERAPEUTICS-LLC
COMPLEX-THERAPEUTICS-LLC
62%
settlement gain on terminated contracts in 2025. Interest Income, Interest Expense, Other Rental Income, Gain on Contract Termination, and Other (Expense) Income, Net Interest income, interest expens…
COMPLEX-THERAPEUTICS-MEZZANINE-LLC
COMPLEX-THERAPEUTICS-MEZZANINE-LLC
62%
settlement gain on terminated contracts in 2025. Interest Income, Interest Expense, Other Rental Income, Gain on Contract Termination, and Other (Expense) Income, Net Interest income, interest expens…
CONTINGENCIES-LEASES-COMPANY
CONTINGENCIES-LEASES-COMPANY
62%
expensed when the milestone results are achieved. Recent Accounting Pronouncements Not Yet Adopted In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Upda…
MIDLAND-NATIONAL-LIFE-INSURANCE-COMPANY
MIDLAND-NATIONAL-LIFE-INSURANCE-COMPANY
62%
settlement gain on terminated contracts in 2025. Interest Income, Interest Expense, Other Rental Income, Gain on Contract Termination, and Other (Expense) Income, Net Interest income, interest expens…
Q-EMERGING-GROWTH-COMPANY
Q-EMERGING-GROWTH-COMPANY
62%
uccessfully commercialize; • the cost of commercialization activities of any product candidates, if approved for sale, including marketing, sales and distribution costs; • the timing, receipt and amo…
Instil Bio, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TIL-DEBT-12984
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
TIL-DEBT
Debt stack $85.2M
90%
Market cache reports total debt of $85.2M.
Instil Bio, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Instil Bio, Inc..
Instil Bio, Inc. Ownership
Holder
Name
Confidence
Evidence
TIL-OWNER-BML-CAPITAL-MANAGEMENT-LLC
BML Capital Management, LLC
90%
13F overlay lists BML Capital Management, LLC as top holder; 31 tracked holders.
Instil Bio, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
